ArticleBMC gastroenterology2025
Long-term efficacy of transarterial chemoembolization in the treatment of recurrent hepatocellular carcinoma.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Analysis of risk factors and prediction of prognosis in patients with primary liver cancer undergoing transarterial chemoembolization.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe purpose of this study was to evaluate the efficacy and safety of transarterial chemoembolization (TACE) for the treatment of patients with recurrent HCC after surgical operation (SR-HCC) and to compare the results with those of the patients with recurrent HCC after TACE (TR-HCC).
methodsThis retrospective study investigated a series of patients who underwent TACE after recurrence from January 2014 to June 2023 in our medical center. Overall survival (OS), therapeutic response and survival rates were compared between the two groups.
resultsA total of 236 eligible patients were included in this study, including 139 patients in the TR-HCC group and 97 patients in the SR-HCC group. The objective response rate of TR-HCC patients was 46.0%, and that of SR-HCC patients was 76.3% (P < 0.001). While the disease control rate of TR-HCC patients was 71.9%, and that of SR-HCC patients was 89.6% (P < 0.001). Before PSM, the median OS in the SR-HCC group was significantly greater than that in the TR-HCC group (OS: 41 months vs. 22 months, P = 0.005). After PSM, the median OS was 24 months (95% CI 20 months, 28 months) in the TR-HCC group and 43 months (95% CI 29 months, 55 months) in the SR-HCC group (P = 0.014). Multivariate analysis suggested that aspartate aminotransferase (AST) levels was significantly related to OS.
conclusionPatients who experienced recurrence after surgical resection who treated with TACE achieved positive results. And we believe that TACE could be a possible treatment for patients with HCC after surgical resection, especially those who are not suitable for re-resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.